Hemolytic and Antifungal Activity of Liposome-Entrapped Amphotericin B Prepared by the Precipitation Method

References

• Hermans P. E., Keys T. F. Antifungal agents used for deep-seated mycotic infections. Mayo Clin. Proc. 1983; 58: 223–231
   PubMed Web of Science ®Google Scholar
• Horn R., Wong B., Kiehn T. E., Amstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev. Infect. Dis. 1985; 7: 646–655
   PubMedGoogle Scholar
• Khutorsky V. E. Structures of amphotericin B-cholesterol complex. Biochim. Biophys. Acta 1992; 1108: 123–127
   PubMed Web of Science ®Google Scholar
• Hoogevest P. V., Kruijff B. D. Effect of amphotericin B on cholesterol-containing liposomes of egg phosphatidylcholine and didocosenoyl phosphatidyl-choline—A refinement of the model for the formation of pores by amphotericin B in membranes. Biochim. Biophys. Acta 1978; 511: 397–407
   PubMedGoogle Scholar
• De Kruijff B., Demel R. A. Polyene antibiotic-sterol interactions in membranes of Acholeplasma Laidlawii cells and lecithin liposomes. II. Temperature dependence of the polyene antibiotic-sterol complex formation. Biochim. Biophys. Acta 1974; 339: 44–56
   PubMedGoogle Scholar
• Bittman R., Chen W. C., Anderson O. R. Interaction of Filipin III and amphotericin B with lecithin-sterol vesicles and cellular membrane.- Spectral and electron microscope studies. Biochemistry 1974; 13: 1364–1373
   PubMed Web of Science ®Google Scholar
• Kotler-Brajtburg J., Medoff G., Kobayashi G. S., Boggs S., Schlessinger D., Pandey R. C., Rinehart K. L., Jr. Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob. Agent Chemother. 1979; 15: 716–722
   PubMed Web of Science ®Google Scholar
• Adams T. H., Wong R. G., Norman A. W. Studies on the mechanism of action of calciferol. II. Effects of the polyene antibiotic, Filipin, on vitamin D-mediated calcium transport. J. Biol. Chem. 1970; 245: 4432–4442
   PubMed Web of Science ®Google Scholar
• Burgess J. L., Birchall R. Nephrotoxicity of amphotericin B with emphasis on changes in tubular function. Am. J. Med. 1972; 53: 77–84
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Juliano R. L. Application of liposomes to the delivery of antifungal agents. Liposomes: From Biophysics to Therapeutics, M. J. Ostro. Marcel Dekker, Inc., New York 1987; 253–276
   Google Scholar
• Mehta R., Lopez-Berestein G., Hopfer R., Mills K., Juliano R. L. Liposomal amphotericin B is toxic to fungal cell but not to mammalian. Biochim. Biophys. Acta 1984; 770: 230–243
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Mehta R. R., Hopfer L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin. B. J. Infect. Dis. 1983; 147: 939–945
   Google Scholar
• Tremblay C., Barza M., Fiore C., Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 1984; 26: 170–173
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M., Reuben J., Juliano R. L., Bodey G. P. Liposomal amphotericin B for treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 1985; 151: 704–710
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Mehta R., Hopfer R., Mehta K., Hersh E. M., Juliano R. L. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Delivery 1983; 1: 37–41
   PubMedGoogle Scholar
• Juliano R. L., Grant C. M. W., Barber K. R., Kalp M. A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Molecular Pharmacol. 1986; 31: 1–11
   Web of Science ®Google Scholar
• Boni L., Cullis P. R., Durning A. G., Janoff A. S., Kearns J. J., Klimchak R., Lenk R. P., Madden T., Portnoff J. Low toxicity drug-lipid systems, European Patent Specification. 0282405B1, 1995
   Google Scholar
• Vaskovsky V. E., Kostetsky E. Y., Vasendin I. M. A universal reagent for phospholipid analysis. J. Chromatogr. 1975; 114: 129–141
   PubMed Web of Science ®Google Scholar
• Jullien S., Brajtburg J., Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim. Biophys. Acta 1990; 1021: 39–45
   PubMed Web of Science ®Google Scholar
• Perkins W. R., Minchey S. R., Boni L. T., Swenson C. E., Popescu M. C., Pasternack R. F., Janoff A. S. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1992; 1107: 271–282
   PubMed Web of Science ®Google Scholar
• Borlard J., Seigneret M., Boudet G. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B—Lipid state and cholesterol content dependence. Biochim. Biophys. Acta 1980; 599: 280–293
   PubMed Web of Science ®Google Scholar
• Balakrishnan A. R., Easwaran K. R. K. CD and NMR studies on the aggregation of amphotericin B in solution. Biochim. Biophys. Acta 1993; 1148: 269–277
   PubMed Web of Science ®Google Scholar
• Kim J.-C., Lee E.-O., Yang J. W., Choi T. B., Kim J.-D. Complexation of amphotericin B with egg phosphatidylcholine liposomes. Archives of Pharmaceutic 1995; 18: 84–89
   Google Scholar
• Janoff A. S., Boni L. T., Popescu M. C., Minchey S. R., Cullis P. R., Madden T. D., Taraschi T., Gruner S. M., Shyamsunder E., Tate M. W., Mendelsohn R., Bonner D. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. 1988; 85: 6122–6126
   PubMed Web of Science ®Google Scholar